Archive · 6 Sep 2026
GLP-1 Weight Loss Requires Metabolic Health, Diagnosis And Supervision
Obesity is a long-term health condition, not simply a problem of willpower.
A person’s thyroid, pancreas and gut can all affect weight and blood sugar.
Sometimes an underactive thyroid or insulin resistance makes losing weight harder.
In India, health problems such as diabetes and heart disease can appear at lower weights than in some Western populations.
GLP-1 medicines can help some people lose weight and improve blood sugar.
They work best alongside changes in eating and physical activity.
These medicines should not be bought online or used without a doctor’s advice.
Doctors should check for problems such as thyroid disease before starting treatment.
India’s Obesity and Metabolic Surgery Society and Endocrine Society issued a joint consensus with 55 recommendations based on input from 78 experts.
The consensus treats obesity as a chronic disease influenced by factors including thyroid function, insulin resistance and other metabolic conditions.
South Asians can develop diabetes and heart disease at lower body weights, making standard weight measures potentially misleading in India.
Semaglutide’s patent protection ended in India on 20 March 2026, and lower-priced generic versions reportedly reached the market within days.
Experts warn that GLP-1 medicines require medical supervision because unauthorised sales and treatment without proper diagnosis can create risks.
- Who
- The Obesity and Metabolic Surgery Society of India, the Endocrine Society of India, 78 experts and patients considering obesity treatment or GLP-1 medicines.
- What
- The societies published a joint consensus on diagnosing and treating obesity, while the article explains the benefits and risks of GLP-1 medicines.
- When
- The consensus was published earlier this month; semaglutide’s patent protection ended on 20 March 2026.
- Where
- India.
- Why
- To promote less-stigmatising, medically supervised obesity care and address related conditions such as thyroid disorders, insulin resistance and diabetes.
- Consensus contributors
- 78 experts
- Consensus recommendations
- 55
- Patent change
- Original branded semaglutide lost patent protection on 20 March 2026.
- Generic availability
- Generic versions reportedly reached the market within days of the patent change.
- Potential benefits
- GLP-1 medicines can support weight loss and improve blood sugar control in people with type 2 diabetes when appropriately used.
- Main safety concern
- Authorities have raised concerns about unauthorised GLP-1 sales through pharmacies, wellness clinics and online platforms.
- Suggested assessment
- The article recommends considering thyroid and blood sugar testing together when unexplained weight gain, fatigue or difficult-to-control blood sugar occurs.